Press Releases – Theradiag

01/02/2021: Theradiag posts 2020 revenue of 10.4 million, up 8.0%

Post author:Sandrine Boussard
Post published:1 February 2021
Post category:Press Releases

Excellent performance for Theranostics sales, with growth of 15.5% Substantial expansion in activity in the United States, materialized by growth of 34.0% Solid performance for sales in France, driven by IVD activity Cash position at…

14/01/2021: THERADIAG signs a contract to supply ORGENTEC with quality control reagents called Alegria® Check

Post author:Quentin Massé
Post published:14 January 2021
Post category:Press Releases

Croissy-Beaubourg, January 14, 2021, 5:45 pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has signed an partnership contract with ORGENTEC, a German…

11/01/2021: THERADIAG announces CE marking for four new i-Tracker® test kits for biotherapy monitoring

Post author:Quentin Massé
Post published:11 January 2021
Post category:Press Releases

Croissy-Beaubourg, January 11, 2021, 5:45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained CE marking for four additional i-Tracker® test kits…